Ipsen To Acquire Albireo Accelerating Growth In Rare Disease With Treatments For Several Pediatric Liver Diseases
Ipsen To Acquire Albireo Accelerating Growth In Rare Disease With Treatments For Several Pediatric Liver Diseases
01/09/23, 6:00 AM
Location
boulogne billancourt
Industry
pharmaceutical
health care
therapeutics
biotechnology
Regulatory News:
Company Info
Location
Boulogne Billancourt, Ile-de-France, France
Company info
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.
Tazverik® is a registered trademark of Epizyme.